Despite improved clinical outcomes in advanced/metastatic HR+/HER2– breast cancer, the utility of CDK4/6 inhibitors is limited by intrinsic resistance (in approximately 10% of patients) and the acquired resistance that inevitably emerges over time [3,17]. This evidence concerns the gene ERBB2 and breast cancer.